CN102895177A - Metronidazole mucilage and preparation method thereof - Google Patents
Metronidazole mucilage and preparation method thereof Download PDFInfo
- Publication number
- CN102895177A CN102895177A CN201210408765XA CN201210408765A CN102895177A CN 102895177 A CN102895177 A CN 102895177A CN 201210408765X A CN201210408765X A CN 201210408765XA CN 201210408765 A CN201210408765 A CN 201210408765A CN 102895177 A CN102895177 A CN 102895177A
- Authority
- CN
- China
- Prior art keywords
- metronidazole
- mucilage
- parts
- water
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a metronidazole mucilage which is characterized by comprising the following components in parts by weight: 1000 parts of water, 1-10 parts of metronidazole, 10-300 parts of glycerol and/or propylene glycol, 0.1-10 parts of chlorhexidine, 1-100 parts of polyethylene oxide, 5-100 parts of polyoxyethylene polypropylene oxide copolymer and 0.05-0.5 parts of EDTA (Ethylene Diamine Tetraacetic Acid) disodium. The invention also discloses a preparation method of the metronidazole mucilage, comprising the steps of dissolving metronidazole by using water, adding other components, and fully and uniformly mixing to form a colloidal solution. The metronidazole mucilage disclosed by the invention has the due efficacy of metronidazole drugs and is capable of simulating cervix uteri, vagina mucus and moist local ecological environment of healthy women, suitable for the treatment and the rehabilitation protection of female reproductive tract infections, menopause vaginitis and reproductive tract infection after the uterus ovarian surgery and capable of overcoming the defect that the dispersion of traditional vaginal effervescent tablets, vaginal suppositories and lotions may be influenced due to insufficient environmental moisture.
Description
Technical field
The present invention relates to a kind of pharmaceutical preparation, relate in particular to a kind of metronidazole mucilage; In addition, the invention still further relates to the preparation method of this metronidazole mucilage.
Background technology
Metronidazole is treatment climacteric women and the vaginitis of ovary and uterus hands postoperative patient and the common medicine of senile vaginitis, dosage form has vagina effervescence agent, vaginal suppository, and these dosage forms obviously have to be affected the moistening hydrophilic environment of vagina and make it that defective of dry sensation be arranged.
The ultimate principle of vagina effervescence is simultaneously carbon dioxide gas formation of neutralization reaction band medicine foam to occur under the moisture existence condition of acid-base material in vaginal environment that contains in the tablet medicine is disperseed, vaginal suppository is from the solid-state process that is melted into liquid, except temperature factor, moisture also is essential condition, patient and middle and aged women for vaginal secretion liquid deficiency, women with the physiology congenital day after tomorrow of hyposecretion, above-mentioned dosage form may affect medicine and disperse because environment moisture content is not enough, obviously be inappropriate, the other drug of wishing clinically to overcome defects replaces.
Summary of the invention
Technical problem to be solved by this invention is to provide a kind of metronidazole mucilage; it can should have drug effect simultaneously in the performance of metronidazole medicine; simulation healthy women cervix uteri, vaginal mucus and moistening hydrophilic local ecological environment; be conducive to the treatment of female genital tract infection and rehabilitation protection, be particularly suitable for treating climacteric vaginitis and the ovary and uterus operation after reproductive tract infection.
Crude drug and adjuvant that the present invention adopts all meet " the regulation of Chinese pharmacopoeia or " British Pharmacopoeia ", " American Pharmacopeia ".
For solving the problems of the technologies described above, the invention provides a kind of metronidazole mucilage, contain the component of following weight portion: 1000 parts in water, metronidazole 1-10 part, glycerol and/or 10 ~ 300 parts of propylene glycol, 0.1 ~ 10 part of chlorhexidine, 1 ~ 100 part of poly(ethylene oxide), 5 ~ 100 parts of poloxalkols, 0.05 ~ 0.5 part of EDETATE SODIUM.
Preferably, the molecular weight of described poly(ethylene oxide) is between 100 ~ 12000.
Preferably, described chlorhexidine is acetate, hydrochlorate or gluconate.
The present invention also provides the preparation method of above-mentioned metronidazole mucilage, comprises the steps:
Step 1: metronidazole is dissolved with suitable quantity of water, sneak into glycerol and/or propylene glycol, poloxalkol and poly(ethylene oxide), make fully to be mixed into colloid solution.
Step 2: just suitable quantity of water is dissolved chlorhexidine, EDETATE SODIUM.
Step 3: the solution that step 2 obtains is sneaked in the colloid solution that is obtained by step 1 again, make abundant mixing.
Preferably, in the step 1, described blender is that container or the homogenizer class of belt stirrer commonly used mixed apparatus.
Preferably, in the step 3, after the described abundant mixing, regulate PH at 6.0-7.0.
The metronidazole mucilage of the inventive method preparation meets the China national drug standard.
The consumption of metronidazole mucilage of the present invention and the course for the treatment of can appropriately adjust according to patient's age, the light and heavy degree of disease, but are generally vagina administration 2 times every day, each 5ml, before getting up morning and evening just before going to bed each once, take 5-7 day as a course for the treatment of.
The present invention has following beneficial effect: the postoperative patient Yi Fasheng of the women in climacteric or menopause and ovary and uterus anaerobic infection; because secretion reduces; mucosa becomes dry and lacks lubricated and protected acidic; so how with the vaginovulvar puckery calcination excitement of itching; be difficult to stand, affect quality of life.Metronidazole mucilage of the present invention can be naturally equably affine, stick, be covered in the reproductive tract mucomembranous surface; not only can make metronidazole performance anti-inflammation drug effect; and protect impaired reproductive tract mucosa; replenish simultaneously due lubricated moisturizing; keep specific acid or alkali environment, provide condition for recovering preventing mechanism.Metronidazole mucilage simulation healthy women cervix uteri/vaginal mucus of the present invention and moistening hydrophilic local ecological environment; be more conducive to the treatment of female genital tract infection and rehabilitation protection, overcome the defective (traditional vagina effervescence agent, vaginal suppository, lotion may affects because environment moisture content is not enough the medicine dispersion) of vagina effervescence agent, vaginal suppository, lotion.Metronidazole mucilage of the present invention has kept above-mentioned enough advantages of dosage form property of medicine persistent period, it is a kind of homodisperse medicine aqueous solution, do not need evolution process and relatively long onset time from the solid to liquid, so onset time rapidly and keep enough durations, can with vaginal mucosa preferably compatible with contact, bring comparatively comfortable subjective feeling to moistening-----this meeting with local environment necessity to user simultaneously, unlikely generation drying and foreign body sensation, as seen, metronidazole mucilage of the present invention has solved traditional metronidazole agent (such as the vagina effervescence agent, vaginal suppository, lotion etc.) insurmountable technical problem has reached the unforeseeable technique effect of traditional metronidazole agent.The present invention contains the metronidazole suppository contrast of mucilage and the 500mg of 37.5mg metronidazole, and curative effect is similar.
The specific embodiment
The present invention is described in further detail by the following examples:
Embodiment one:
With 7.5g metronidazole 800ml water dissolution, insert in the container; 40g glycerol, 10g propylene glycol, 10g poloxalkol and 30g poly(ethylene oxide) 8000 are sneaked into, be stirred to material dissolution and become colloidal solution shape; In another container 0.7g chlorhexidine acetate, 0.1gEDTA disodium are sneaked in the above-mentioned colloid solution after with the 200ml water dissolution, fully stir evenly, regulating PH is 6.0, places packing after 12 hours, gets metronidazole mucilage finished product.
Embodiment two:
With 75g metronidazole 8000ml water dissolution, insert in the container; 300g glycerol, 200g propylene glycol, 100g poloxalkol and 300g poly(ethylene oxide) 8000 are sneaked into, put that homogenizing to material dissolution becomes colloidal solution shape in the homogenizer; In another container 7g chlorhexidine acetate, 1gEDTA disodium are sneaked in the above-mentioned colloid solution after with the 2000ml water dissolution, fully stir evenly, regulating PH is 7.0, places packing after 10 hours, gets the metronidazole mucilage.
Embodiment three:
With 1g metronidazole 800ml water dissolution, insert in the container; 50g glycerol, 100g poloxalkol and 1g poly(ethylene oxide) 6000 are sneaked into, be stirred to material dissolution and become colloidal solution shape; In another container 10g Chlorhexidine hydrochloride, 0.5g EDETATE SODIUM are sneaked in the above-mentioned colloid solution after with the 200ml water dissolution, regulating PH is 6.5, fully stirs evenly, and gets the metronidazole mucilage.
Embodiment four:
With 5g metronidazole 800ml water dissolution, insert in the container; 10g glycerol, 20g poloxalkol and 100g poly(ethylene oxide) 6000 are sneaked into, be stirred to material dissolution and become colloidal solution shape; In another container 10g chlorhexidine acetate, 0.1gEDTA disodium are sneaked in the above-mentioned colloid solution after with the 200ml water dissolution, fully stir evenly, regulating PH is 7.0, gets the metronidazole mucilage.
Embodiment five:
With 10g metronidazole 800ml water dissolution, insert in the container; 300g propylene glycol, 5g poloxalkol and 100g poly(ethylene oxide) 6000 are sneaked into, be stirred to material dissolution and become colloidal solution shape; In another container 0.5g chlorhexidine gluconate, 0.05g EDETATE SODIUM are sneaked in the above-mentioned colloid solution after with the 200ml water dissolution, fully stir evenly, regulating PH is 7.0, gets the metronidazole mucilage.
Embodiment six:
With 5g metronidazole 800ml water dissolution, insert in the container; 100g glycerol, 5g poloxalkol and 100g poly(ethylene oxide) 4000 are sneaked into, be stirred to material dissolution and become colloidal solution shape; In another container 0.1g chlorhexidine acetate, 0.05g EDETATE SODIUM are sneaked in the above-mentioned colloid solution after with the 200ml water dissolution, fully stir evenly, regulating PH is 7.0, gets the metronidazole mucilage.
Below by clinical verification beneficial effect of the present invention is described in further detail:
Bacterial vaginosis case and the trichomonal vaginitis case that will meet clinical criteria are divided into two groups at random: tested group of 101 examples, 38.33 ± 5.12 years old mean age, wherein treat trichomonal vaginitis 81 examples, treatment bacterial vaginosis 20 examples.Matched group 53 examples, are wherein treated trichomonal vaginitis 43 examples, treatment bacterial vaginosis 10 examples at 36.36 ± 4.9 years old mean age.
Take metronidazole mucilage of the present invention as tested group of medicine, commercially available metronidazole suppository (500mg/ grain bolt) is the matched group medicine.Medication sees Table 1:
Table 1: medication
MAIN OUTCOME MEASURES result and analysis in table 2, table 3, table 4:
Table 2: treat trichomonal vaginitis symptom, sign efficacy analysis for two groups
Table 3: treat bacterial vaginosis symptom, sign efficacy analysis for two groups
Table 4: two groups for the treatment of total effectses analysis
The clinical verification conclusion (of pressure testing): treat after 14 days, tested group 101 the example and matched group 53 examples in effective percentage be respectively 88.12% and 92.46%, P＞0.05(see Table 4), show the two curative effect there was no significant difference.Untoward reaction occurs in tested group of none example of 101 routine patients.Metronidazole mucilage of the present invention has the characteristics that diffuse into rapidly the medicinal liquid film in intravaginal, more easily arrive the affected part that solid drugs is difficult to arrive, vagina fold place, and easily keep reservation.Contain the metronidazole suppository curative effect of the mucilage of 37.5mg metronidazole and 500mg without significant difference, this property of medicine shape is similar to normal secretion, and patient's foreign body sensation is light, without bad sensation, is easy to psychological endurance.
Claims (6)
1. metronidazole mucilage, it is characterized in that, comprise the component of following weight portion: 1000 parts in water, metronidazole 1-10 part, glycerol and/or 10 ~ 300 parts of propylene glycol, 0.1 ~ 10 part of chlorhexidine, 1 ~ 100 part of poly(ethylene oxide), 5 ~ 100 parts of poloxalkols, 0.05 ~ 0.5 part of EDETATE SODIUM.
2. metronidazole mucilage as claimed in claim 1 is characterized in that, the molecular weight of described poly(ethylene oxide) is between 100 ~ 12000.
3. metronidazole mucilage as claimed in claim 1 is characterized in that, described chlorhexidine is acetate, hydrochlorate or gluconate.
4. the preparation method of a metronidazole mucilage as claimed in claim 1 is characterized in that, in turn includes the following steps:
Step 1: metronidazole is dissolved with suitable quantity of water, sneak into glycerol and/or propylene glycol, poloxalkol and poly(ethylene oxide), in blender, make fully to be mixed into colloid solution;
Step 2: suitable quantity of water is dissolved chlorhexidine, EDETATE SODIUM;
Step 3: the solution that step 2 obtains is sneaked in the colloid solution that is obtained by step 1, make abundant mixing.
5. the preparation method of metronidazole mucilage as claimed in claim 4 is characterized in that, in the step 1, described blender is that container or the homogenizer class of belt stirrer commonly used mixed apparatus.
6. the preparation method of metronidazole mucilage as claimed in claim 4 is characterized in that, in the step 3, after the described abundant mixing, regulates PH at 6.0-7.0.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210408765.XA CN102895177B (en) | 2012-10-23 | 2012-10-23 | Metronidazole mucilage and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210408765.XA CN102895177B (en) | 2012-10-23 | 2012-10-23 | Metronidazole mucilage and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102895177A true CN102895177A (en) | 2013-01-30 |
| CN102895177B CN102895177B (en) | 2014-05-07 |
Family
ID=47567868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210408765.XA Active CN102895177B (en) | 2012-10-23 | 2012-10-23 | Metronidazole mucilage and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102895177B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552114A (en) * | 2012-03-19 | 2012-07-11 | 段亚东 | Metronidazole ophthalmic gel and preparation method and application thereof |
-
2012
- 2012-10-23 CN CN201210408765.XA patent/CN102895177B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552114A (en) * | 2012-03-19 | 2012-07-11 | 段亚东 | Metronidazole ophthalmic gel and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102895177B (en) | 2014-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5118633B2 (en) | Mucoadhesive xyloglucan-containing preparations useful in medical devices and pharmaceutical preparations | |
| AU2002246916B2 (en) | Bioadhesive cell foam film of sustained-release delivery | |
| CN101744833B (en) | Medicinal composition for treating bacterial vaginitis | |
| TW200831107A (en) | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens | |
| WO2006114061A1 (en) | A composition and method of regulating and maintaining the vaginal bacterial flora and the normal acidity in the vaginal | |
| CN104906066A (en) | Lincomycin hydrochloride compound vaginal effervescent tablets and preparation method thereof | |
| US20170246230A1 (en) | Pharmaceutical composition for treating infertility, and preparation method and use thereof | |
| WO2020051973A1 (en) | Application of terra flava usta in preparation of medicaments for preventing and treating allergic diseases, mental diseases, metabolic diseases, and endocrine disorders | |
| CN114246918A (en) | Traditional Chinese medicine composition for treating hashimoto thyroiditis and preparation method thereof | |
| JP2002543128A (en) | Treatment of female arousal disorder | |
| TWI280877B (en) | Beta-agonists for treating endometriosis or infertility, or improving fertility | |
| CN101099730A (en) | Oral solid preparation containing ambroxol hydrochloride and guaifenesin active components | |
| CN102895177B (en) | Metronidazole mucilage and preparation method thereof | |
| EP3501507B1 (en) | Macrogols for application to the mucosa, and therapeutic uses thereof | |
| CN101912376B (en) | Matrine vaginal effervescent tablets with bilayer structure and preparation method | |
| JP2010189409A (en) | Use of oestrogen in manufacture of composition containing oestrogen for treatment of atrophic vaginitis | |
| CN102283800B (en) | Sertaconazole nitrate suppository for treating vaginitis and preparation method thereof | |
| CN104887642A (en) | Lincomycin vaginal effervescent tablets and preparation method | |
| WO2008061409A1 (en) | Enteric coated formulation comprising alkaline active agent and its preparation process | |
| CN113750205A (en) | Traditional Chinese medicine composition for relieving and/or treating female reproductive system diseases | |
| CN114129528A (en) | Novel sildenafil citrate preparation with clinical advantages and preparation process and application thereof | |
| Vasudeva et al. | Mirena and nuvaring in management in dysfunctional uterine bleeding | |
| CN1966035A (en) | Chinese medicinal formulation for treating children's hyperkinetic syndrome | |
| CN109646438A (en) | The application of demethyl coclaurine or its hydrochloride in preparation treatment rhinitis drug | |
| CN109528708A (en) | Application of the Kaempferol in preparation treatment rhinitis drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200908 Address after: 588 Longchang Road, Yangpu District, Shanghai, 201499_ Room 2301-2303, No.2 (centralized registration place) Patentee after: Shanghai ruixiao Medical Technology Co., Ltd Address before: 200434 room 57, No. 289, Lane 202, Memorial Road, Shanghai, Yangpu District Patentee before: Wang Xiaoming |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201231 Address after: Room 101, building 763, 2865-2 Zhoujiazui Road, Yangpu District, Shanghai 200082 Patentee after: Shanghai Rui Rui Biomedical Technology Co.,Ltd. Address before: 201499 588 Longchang Road, Yangpu District, Shanghai_ Room 2301-2303, No.2 (centralized registration place) Patentee before: Shanghai ruixiao Medical Technology Co., Ltd |